 Connection
Charles Daley to Microbial Sensitivity Tests
This is a "connection" page, showing publications Charles Daley has written about Microbial Sensitivity Tests.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.597 |
|
|
|
-
Nguyen MH, Calado Nogueira de Moura V, Keepers TR, van Ingen J, Daley CL. In vitro susceptibility of 147 international clinical Mycobacterium abscessus isolates to epetraborole and comparators by broth microdilution. J Antimicrob Chemother. 2025 Mar 03; 80(3):713-716.
Score: 0.213
-
Dousa KM, Shin E, Kurz SG, Plummer M, Nantongo M, Bethel CR, Taracila MA, Nguyen DC, Kreiswith BN, Daley CL, Remy KE, Holland SM, Bonomo RA. Synergistic effects of sulopenem in combination with cefuroxime or durlobactam against Mycobacterium abscessus. mBio. 2024 Jun 12; 15(6):e0060924.
Score: 0.201
-
Chen L, Shashkina E, Kurepina N, Calado Nogueira de Moura V, Daley CL, Kreiswirth BN. In vitro activity of cefoxitin, imipenem, meropenem, and ceftaroline in combination with vaborbactam against Mycobacterium abscessus. Antimicrob Agents Chemother. 2024 05 02; 68(5):e0017424.
Score: 0.200
-
van Ingen J, Totten SE, Helstrom NK, Heifets LB, Boeree MJ, Daley CL. In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease. Antimicrob Agents Chemother. 2012 Dec; 56(12):6324-7.
Score: 0.090
-
van Ingen J, Egelund EF, Levin A, Totten SE, Boeree MJ, Mouton JW, Aarnoutse RE, Heifets LB, Peloquin CA, Daley CL. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med. 2012 Sep 15; 186(6):559-65.
Score: 0.088
-
van Ingen J, Totten SE, Heifets LB, Boeree MJ, Daley CL. Drug susceptibility testing and pharmacokinetics question current treatment regimens in Mycobacterium simiae complex disease. Int J Antimicrob Agents. 2012 Feb; 39(2):173-6.
Score: 0.085
-
Singh N, Dangi B, Johnson JJ, Louie A, Karunanidhi A, Curry BN, Mitarai S, Daley CL, Hobbie SN, Bulman ZP. Pharmacodynamic assessment of apramycin against Mycobacterium abscessus in a hollow fibre infection model. J Antimicrob Chemother. 2025 May 02; 80(5):1309-1314.
Score: 0.054
-
Shin E, Dousa KM, Taracila MA, Bethel CR, Nantongo M, Nguyen DC, Akusobi C, Kurz SG, Plummer MS, Daley CL, Holland SM, Rubin EJ, Bulitta JB, Boom WH, Kreiswirth BN, Bonomo RA. Durlobactam in combination with ?-lactams to combat Mycobacterium abscessus. Antimicrob Agents Chemother. 2025 Feb 13; 69(2):e0117424.
Score: 0.053
-
Calado Nogueira de Moura V, Nguyen MH, Hunkins JJ, Daley CL, Khare R. In vitro susceptibility patterns for slowly growing non-tuberculous mycobacteria in the USA from 2018 to 2022. J Antimicrob Chemother. 2023 12 01; 78(12):2849-2858.
Score: 0.049
-
Hunkins JJ, de-Moura VC, Eddy JJ, Daley CL, Khare R. In vitro susceptibility patterns for rapidly growing nontuberculous mycobacteria in the United States. Diagn Microbiol Infect Dis. 2023 Mar; 105(3):115882.
Score: 0.046
-
Dousa KM, Nguyen DC, Kurz SG, Taracila MA, Bethel CR, Schinabeck W, Kreiswirth BN, Brown ST, Boom WH, Hotchkiss RS, Remy KE, Jacono FJ, Daley CL, Holland SM, Miller AA, Bonomo RA. Inhibiting Mycobacterium abscessus Cell Wall Synthesis: Using a Novel Diazabicyclooctane ?-Lactamase Inhibitor To Augment ?-Lactam Action. mBio. 2022 02 22; 13(1):e0352921.
Score: 0.043
-
Davidson RM, Hasan NA, Epperson LE, Benoit JB, Kammlade SM, Levin AR, Calado de Moura V, Hunkins J, Weakly N, Beagle S, Sagel SD, Martiniano SL, Salfinger M, Daley CL, Nick JA, Strong M. Population Genomics of Mycobacterium abscessus from U.S. Cystic Fibrosis Care Centers. Ann Am Thorac Soc. 2021 12; 18(12):1960-1969.
Score: 0.043
-
Nguyen DC, Dousa KM, Kurz SG, Brown ST, Drusano G, Holland SM, Kreiswirth BN, Boom WH, Daley CL, Bonomo RA. "One-Two Punch": Synergistic ?-Lactam Combinations for Mycobacterium abscessus and Target Redundancy in the Inhibition of Peptidoglycan Synthesis Enzymes. Clin Infect Dis. 2021 10 20; 73(8):1532-1536.
Score: 0.042
-
Marras SAE, Chen L, Shashkina E, Davidson RM, Strong M, Daley CL, Kreiswirth BN. A Molecular-Beacon-Based Multiplex Real-Time PCR Assay To Distinguish Mycobacterium abscessus Subspecies and Determine Macrolide Susceptibility. J Clin Microbiol. 2021 07 19; 59(8):e0045521.
Score: 0.041
-
Dousa KM, Kurz SG, Taracila MA, Bonfield T, Bethel CR, Barnes MD, Selvaraju S, Abdelhamed AM, Kreiswirth BN, Boom WH, Kasperbauer SH, Daley CL, Bonomo RA. Insights into the l,d-Transpeptidases and d,d-Carboxypeptidase of Mycobacterium abscessus: Ceftaroline, Imipenem, and Novel Diazabicyclooctane Inhibitors. Antimicrob Agents Chemother. 2020 07 22; 64(8).
Score: 0.039
-
Huh HJ, Kim SY, Shim HJ, Kim DH, Yoo IY, Kang OK, Ki CS, Shin SY, Jhun BW, Shin SJ, Daley CL, Koh WJ, Lee NY. GenoType NTM-DR Performance Evaluation for Identification of Mycobacterium avium Complex and Mycobacterium abscessus and Determination of Clarithromycin and Amikacin Resistance. J Clin Microbiol. 2019 08; 57(8).
Score: 0.036
-
Kim DH, Jhun BW, Moon SM, Kim SY, Jeon K, Kwon OJ, Huh HJ, Lee NY, Shin SJ, Daley CL, Koh WJ. In Vitro Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates. Antimicrob Agents Chemother. 2019 08; 63(8).
Score: 0.036
-
Kwak N, Dalcolmo MP, Daley CL, Eather G, Gayoso R, Hasegawa N, Jhun BW, Koh WJ, Namkoong H, Park J, Thomson R, van Ingen J, Zweijpfenning SMH, Yim JJ. Mycobacterium abscessus pulmonary disease: individual patient data meta-analysis. Eur Respir J. 2019 07; 54(1).
Score: 0.036
-
Kim SY, Moon SM, Jhun BW, Kwon OJ, Huh HJ, Lee NY, Lee SH, Shin SJ, Kasperbauer SH, Huitt GA, Daley CL, Koh WJ. Species Distribution and Macrolide Susceptibility of Mycobacterium fortuitum Complex Clinical Isolates. Antimicrob Agents Chemother. 2019 06; 63(6).
Score: 0.036
-
Kim SY, Jhun BW, Moon SM, Shin SH, Jeon K, Kwon OJ, Yoo IY, Huh HJ, Ki CS, Lee NY, Shin SJ, Daley CL, Suh GY, Koh WJ. Mutations in gyrA and gyrB in Moxifloxacin-Resistant Mycobacterium avium Complex and Mycobacterium abscessus Complex Clinical Isolates. Antimicrob Agents Chemother. 2018 09; 62(9).
Score: 0.034
-
Choi H, Kim SY, Kim DH, Huh HJ, Ki CS, Lee NY, Lee SH, Shin S, Shin SJ, Daley CL, Koh WJ. Clinical Characteristics and Treatment Outcomes of Patients with Acquired Macrolide-Resistant Mycobacterium abscessus Lung Disease. Antimicrob Agents Chemother. 2017 10; 61(10).
Score: 0.032
-
Yang B, Jhun BW, Moon SM, Lee H, Park HY, Jeon K, Kim DH, Kim SY, Shin SJ, Daley CL, Koh WJ. Clofazimine-Containing Regimen for the Treatment of Mycobacterium abscessus Lung Disease. Antimicrob Agents Chemother. 2017 06; 61(6).
Score: 0.031
-
Mase SR, Jereb JA, Gonzalez D, Martin F, Daley CL, Fred D, Loeffler AM, Menon LR, Bamrah Morris S, Brostrom R, Chorba T, Peloquin CA. Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands. Pediatr Infect Dis J. 2016 Apr; 35(4):414-21.
Score: 0.029
-
Shojaei H, Daley C, Gitti Z, Hashemi A, Heidarieh P, Moore ERB, Naser AD, Russo C, van Ingen J, Tortoli E. Mycobacterium iranicum sp. nov., a rapidly growing scotochromogenic species isolated from clinical specimens on three different continents. Int J Syst Evol Microbiol. 2013 Apr; 63(Pt 4):1383-1389.
Score: 0.022
-
Koh WJ, Jeon K, Lee NY, Kim BJ, Kook YH, Lee SH, Park YK, Kim CK, Shin SJ, Huitt GA, Daley CL, Kwon OJ. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med. 2011 Feb 01; 183(3):405-10.
Score: 0.020
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|